日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy

通过对TIGIT进行碱基编辑,重编程自然杀伤细胞中的CD155信号通路,从而增强癌症免疫疗法的疗效。

Fang, Cheng; Li, Guanglei; Han, Min; Wang, Yiming; Yu, Wenxia; Hu, Dan; Luo, Jiaojiao; Wang, Lixin; Fan, Wenwen; Wang, Liling; Xu, Tianhong; Huang, Xingxu; Yao, Chao; Zhu, Shiguo

Regulation of the immune CD155-CD226-TIGIT axis by cyclin D-CDK4/6

细胞周期蛋白D-CDK4/6对免疫CD155-CD226-TIGIT轴的调控

Fassl, Anne; Palacios Espinoza, Miriam; Butter, Deborah; Kolodziejczyk, Aleksandra; Seehawer, Marco; Hill, Charlotte; Ning, Xiaohan; Branigan, Timothy B; Peñailillo, Johany; Saengboonmee, Charupong; Jadhav, Heta; Charbonnier, Louis-Marie; Waks, Adrienne G; Strawser, Corinne; McDonnell, Donald P; Shapiro, Geoffrey I; Tolaney, Sara M; Polyak, Kornelia; Sammons, Sarah; Wucherpfennig, Kai W; Sicinski, Piotr

Dual targeting of CD155 augments the antitumor efficacy of ROR1-CAR-T cells in ovarian cancer.

双重靶向 CD155 可增强 ROR1-CAR-T 细胞在卵巢癌中的抗肿瘤疗效。

Ye Yingjun, Liu Tingwei, Cheng Chao, Wang Huajing, Shen Jiacheng, He Xiaowen, Xu Shaohua

Association of TIGIT and CD155 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, MSI Status, and Cytokine Profiles in Colorectal Cancer

TIGIT 和 CD155 与 KRAS、NRAS、BRAF、PIK3CA 和 AKT 基因突变、MSI 状态以及细胞因子谱在结直肠癌中的关联

Ochman, Błażej; Limanówka, Piotr; Mielcarska, Sylwia; Kula, Agnieszka; Dawidowicz, Miriam; Hudy, Dorota; Szrot, Monika; Piecuch, Jerzy; Czuba, Zenon; Waniczek, Dariusz; Świętochowska, Elżbieta

CD155 density on target cells drives divergent natural killer cell responses owing to DNAM-1 loss

由于DNAM-1的丢失,靶细胞上CD155的密度驱动着不同的自然杀伤细胞反应。

Saunders, Philippa M; Oates, Clare V L; Hare, Roseanna; Burgess, Mark; Vargas Pavia, Tania Allin; Worboys, Jonathan D; Davis, Daniel M; Brooks, Andrew G

A comprehensive analysis of immune checkpoint receptor-ligand pairs in aortic diseases highlights the immunosuppressive roles of CD155 and CD274

对主动脉疾病中免疫检查点受体-配体对的全面分析突显了CD155和CD274的免疫抑制作用。

Shao, Ying; Saaoud, Fatma; Xu, Keman; Lu, Yifan; Wu, Sheng; Martinez, Laisel; Vazquez-Padron, Roberto; Kosmider, Beata; Wang, Hong; Yang, Xiaofeng

Targeting CD155 in lung adenocarcinoma: A5 nanobody-based therapeutics for precision treatment and enhanced drug delivery

靶向CD155治疗肺腺癌:基于A5纳米抗体的精准治疗和增强药物递送

Noh, Kyunghee; Yi, Soyeon; Kim, Hyeran; Lee, Jieun; Kim, Suhyeon; Yoo, Wonbeak; Jung, Eunkyeong; Choi, Jinsol; Park, Hwangseo; Hwang, Seungha; Kang, Jin Young; Park, Kwang-Hyun; Park, Heewon; Lee, Yong-Kyu; Lim, Eun-Kyung; Kang, Taejoon; Jung, Juyeon

Arecoline upregulates CD155 expression to facilitate immune evasion in oral squamous cell carcinoma

槟榔碱上调CD155表达,促进口腔鳞状细胞癌的免疫逃逸

Wang, Qian; Meng, Yi; Liu, Yuhang; Zhang, Shanshan; Wang, Yian; Chen, Pan; Xiang, Bo; Zhou, Ming; Gong, Zhaojian; Zeng, Zhaoyang; Ge, Junshang; Xiong, Wei

HSP47 inhibition-induced CD155 expression through TRAF2 deubiquitination promotes tumor immune evasion.

HSP47抑制通过TRAF2去泛素化诱导CD155表达,从而促进肿瘤免疫逃逸。

Mou Haochen, Qu Hao, Chen Shixin, Zhang Wenkan, Chen Liang, Wang Zhuli, Eloy Yinwang, Shao Zhenxuan, Zhou Hao, Xue Yucheng, Sun Hangxiang, Wang Fangqian, Chai Xupeng, Zhang Jiahao, Yao Minjun, Zhao Shenzhi, Lei Jiangchu, Jin Lingxiao, Lu Senxu, Li Binghao, Wang Zenan, Ye Zhaoming

CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma

CD155阻断可增强同种异体自然杀伤细胞介导的抗骨肉瘤肿瘤反应

Monica M Cho ,Longzhen Song ,Aicha E Quamine ,Fernanda Szewc ,Lei Shi ,Johnathan D Ebben ,David P Turicek ,Jillian M Kline ,Devin M Burpee ,Emily O Lafeber ,Madison F Phillips ,Amanda S Ceas ,Paul D Bates ,Matthew H Forsberg ,John A Kink ,Amy K Erbe ,Christian M Capitini